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Possible cardiac repair by adult stem cell transplantation is
currently hamperedbypoor cell viability anddelivery efficiency,
uncertain differentiating fate in vivo, the needs of ex vivo cell
expansion, and consequent delay in transplantation after the
onset of heart attack. By the aid of magnetic resonance imaging,
positron emission tomography, and immunohistochemistry, we
show that injection of a hyaluronan mixed ester of butyric and
retinoic acid (HBR) into infarcted rat hearts afforded substantial
cardiovascular repair and recovery of myocardial performance.
HBR restored cardiac [18F]fluorodeoxyglucose uptake and
increased capillary density and led to the recruitment of endog-
enous Stro-1-positive stem cells. A terminal deoxynucleotidyl-
transferase-mediated dUTP nick end labeling assay demon-
strated that HBR-treated hearts exhibited a decrease in the
number of apoptotic cardiomyocytes. In isolated rat cardiomyo-
cytes and Stro-1 stem cells, HBR enhanced the transcription of
vascular endothelial growth factor, hepatocyte growth factor,
kdr,akt, andpim-1. HBR also increased the secretion of vascular
endothelial growth factor and hepatocyte growth factor, sug-
gesting that themixed estermay have recruited bothmyocardial
and Stro-1 cells also. An increase in capillarogenesis was induced
in vitro with medium obtained from HBR-exposed cells. In the
infarctedmyocardium,HBR injection increased histoneH4 acety-
lation significantly. Acetyl-H4 immunoreactivity increased in rat
cardiomyocytes and Stro-1 cells exposed to HBR, compared with
untreated cells. In conclusion, efficient cardiac regenerative
therapy can be afforded by HBR without the need of stem cell
transplantation or vector-mediated gene delivery.
Cardiomyocyte loss during myocardial infarction (MI)3 is
associated with dysfunction of underperfused myocardium,
eventually progressing toward heart failure. Analysis of the res-
cuing potential associated with transplantation of human mes-
enchymal stem cells (hMSCs) in animal models of MI has
recently led to the conclusion that paracrine actions exerted by
adult stem cells through the release of soluble factors might be
importantmechanisms of tissue repair and functional improve-
ment (1, 2). To this end, we have recently shown that hMSCs
isolated from fetal membranes of human term placenta
(FMhMSCs) secreted large amounts of angiogenic, mitogenic,
antiapoptotic, and antifibrotic factors, as compared with
hMSCs isolated from the human bone marrow, significantly
contributing to improved cardiovascular function in infarcted
rat hearts (3). It is noteworthy that ex vivo preconditioning of
FMhMSCs with a mixed ester of hyaluronan with butyric and
retinoic acid (HBR) acted transcriptionally to increase both the
commitment to cardiovascular lineages and the secretion of
trophic mediators, remarkably enhancing stem cell-mediated
improvement in vivo (3).
Here, we directly injected HBR into the myocardium of
infarcted rat hearts and provide evidence that the mixed ester
afforded substantial recovery of myocardial performance with-
out the need of stem cell transplantation. The HBR action was
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tive cells within the injected myocardium. These responses
probably involved the activation of a gene program of paracrine
patterning for myocardial protection and angiogenesis and the
enhanced survival of locally recruited stem cells.
EXPERIMENTAL PROCEDURES
Synthesis of HBR—The procedure for the synthesis and char-
acterization of HBR, and the related chemical structure are
reported in detail elsewhere (4). The primary hydroxyl group in
position 6 of the N-acetyl-D-glucosamine residues in the
polysaccharide backbone is themost reactive toward esterifica-
tion. Briefly, we prepared a double salt of tetrabutylammonium
with two functional groups of hyaluronan, specifically its car-
boxyl and 6-hydroxyl, in order to achieve good solubility in
polar aprotic organic solvents and to increase the nucleophilic-
ity of the oxygen atom at C-6. Retinoylation with retinoyl chlo-
ride, which is the rate-limiting step, was carried out before
butyrylation by means of butyric anhydride and 4-(dimethyl-
amino)pyridine as a hypernucleophilic acylation catalyst (4).
The degree of substitution (DS) was considered as the number
of the esterified OH groups for each repeating unit of hyalu-
ronic acid (GlcNAc-GlcUAdimer). Theweight-averagemolec-
ular weight of HBR, referred to as theweight-average of sodium
hyaluronate, was determined by high performance size exclu-
sion chromatography (4).
Myocardial Infarction (MI)—Studies were performed on
male Wistar rats (n  30, 250–300 g in size). Animals were
sedated (xylazine 14 mg/kg, intraperitoneally), anesthetized
(Zoletil100, 40 mg/kg, intraperitoneally), and ventilated with a
mixture of air and oxygen (1:1), and MI was induced as
described previously (3). Briefly, a thoracotomy was performed
in the left fourth intercostal space, and a permanent surgical
ligation was placed around the left anterior descending coro-
nary artery near its origin with a 6-0 silk suture, during electro-
cardiographicmonitoring for ST changes and arrhythmias. The
chest was closed in layers, and pneumothorax was reduced.
Experimental protocols were approved by the Animal Care
Committee of the ItalianMinistry ofHealth, in accordancewith
Italian law (DL-116, January 27, 1992).
Healthy animals were randomly divided into three experi-
mental groups: 1) MI treated with 100 l of sterile phosphate-
buffered saline (PBS) as vehicle (control group, MI PBS, n
10), 2) MI treated with 100 l of HBR solution (0.2 mg of HBR
per 100 g of rat weight) (treated group,MIHBR, n 10), and
3) sham-operated rats (SHAM, n  10), in which left anterior
descending coronary artery was not occluded. The sterile solu-
tions were injected into the viable myocardium bordering the
infarct zone and the infarcted site 45 min after the coronary
ligation by a syringe with a needle of 24 gauge. The infarct zone
was identified by the pale color of the myocardium. Small ani-
mal positron emission tomography (mPET) and 1.5-tesla mag-
netic resonance imaging (MRI) were performed 4 weeks after
coronary ligation.
Functional Assessment—Regional left ventricular (LV) myo-
cardial glucose uptake was measured by mPET to assess oxida-
tive metabolism, whereas regional contractility and infarct size
were quantified by conventional MRI. For both types of imag-
ing, we used three cross-sectional planes (i.e. basal, middle, and
apical) and six circumferential regions (i.e. anterior, anterior-
lateral, inferolateral, inferior, inferoseptal, and anterior-septal).
LV regionswere selected as described previously (5). Briefly, the
infarcted area comprised segments withmore than 25% of their
area occupied by scar tissue, and the border zone comprised
segments containing less than 25% of scar tissue area and was
immediately contiguous (either circumferentially or longitudi-
nally) to the infarcted area. The remote segments that did not
contain scar tissue were those located outside the border zone.
To assess the relationship between in vivo measurements of
myocardial contractility and metabolism, mPET was per-
formed within 24–36 h after MRI.
MRI Measurements—MRI protocol was performed with a
1.5-tesla clinical whole body scanner (Signa CVI, GE Medical
Systems) by using a phased array send-receive coil for a human
knee (knee PA coil), as described previously (6). An electrocar-
diograph-triggered SSFP (FIESTA) pulse sequence was ac-
quired to assess LV function (parameters: 200-mm field of view,
3-mm slice thickness, no gap, number of excitations 5, two
views per segment, echo time/repetition time 1.6/3.2, flip angle
45°,matrix 192 192, and reconstructionmatrix 256 256). In
each rodent, a total of four LV short axis (to completely cover
ventricular main axis in end diastole) and two LV long axis
views (vertical and horizontal long axis) were acquired. For
each view, 10 cine frames were acquired. For detection of non-
viable myocardium, which appears hyperintense, and for
assessment of LV infarct size, delayed enhancement images
were obtained 3 min after bolus injection of Gadobutrol
(Gadovist; 0.02 mmol per 100 g of body weight) via the tail
vein; images were acquired in the same short axis and long axis
slices as used for cine MRI. An electrocardiograph-triggered
fast gradient echo inversion recovery pulse sequence was uti-
lized with the following parameters: TR 4.2 ms, TE minimum,
flip angle 20°, matrix 192  192, NEX 5, field of view 20–20
mm, slice thickness 3mm, no interslice gap, 1 R-R interval. The
inversion time was fixed to 100 ms and eventually optimized to
null signal from the normal myocardium when appropriate.
Image Processing—To assess the infarct size, the extent of
delayed enhanced areas was measured using a semiautomatic
software, previously validated by us (7). For this purpose, we
used all short axis images and two additional long axis images
for the analysis of the cardiac apex. In each image, the bound-
aries of contrast-enhanced areas were traced andmanually cor-
rected when needed. Contrast-enhanced regions, namely the
infarcted regions, were expressed in grams aswell as in percent-
age of the entire left ventricle. Left ventricle end diastolic and
end systolic volumes, LVmass, and ejection fraction weremea-
sured from the cine images using previously validated software
(Mass, MEDIS).
The infarcted region was detected in cine images by compar-
ison with the respective delayed enhancement image. Then
regional end diastolic and end systolic wall thickness was mea-
sured in the core of the infarcted area, in the border regions, and
in the remote myocardium. Regional contractility was assessed
by employing the end systolic wall thickening in three short-
axis segments (basal, middle, and apical) for correlations with
matched PET slices. Absolute regional wall thickening was cal-
culated in the same regions by the difference between end sys-
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tolic and end diastolic wall thickness. Relative regional wall
thickening was calculated with the formula, end systolic/end
diastolic wall thickness 100, and expressed as a percentage.
PETMeasurements—Each sedated rat was placed on a scan-
ner bed in prone position and received an intravenous injection
of [18F]fluorodeoxyglucose ([18F]FDG; 45MBq) via the tail vein
in a 0.15-ml volume. The residual dose in the syringe was mea-
sured to verify the effective injected dose. The heart was cen-
tered on the field of view. PET was performed with a small
animal positron emission tomograph (GE eXplore Vista DR,
GE Healthcare) (8). The dynamic list mode acquisition was
immediately started for a total time of 30 min. Once the scan
was finished, animalswere placed in a recovery boxwith awarm
temperature until complete recovery. All images were recon-
structed with iterative reconstruction on OSEM 2D (Siemens)
and visualized frame by frame with dedicated software in three
planes (axial, sagittal, and coronal), as described previously (9).
To perform viability analysis in each experimental condition,
dynamic scans were reformatted by adding all frames of the last
10 min of acquisition in order to obtain a static acquisition
image. Semiquantitative analysis of regional LV [18F]FDG
uptake was performed with specific software adapted for ani-
mals (ECTB) (9, 10), using resting scores of 0–4 (0, normal; 1,
equivocal; 2, moderately reduced; 3, severely reduced; 4,
absent).
Tissue Immunohistochemistry—Hearts were arrested in dias-
tole, and 3-mm-thick transverse slices were cut through the
short axis of both ventricles at midseptal level. Macroscopic
infarct size was assessed by nitro blue tetrazolium staining.
Samples were fixed in 10% buffered formalin and embedded in
paraffin, and 4-m-thick sections were used for histological,
immunohistochemical, and immunofluorescence analysis. For
conventional histopathological analysis, sections were stained
with hematoxylin and eosin. Picro-Mallory trichrome staining
was used for determining the degree of fibrosis. Images were
digitized through a video camera (JVC 3CCD video camera,
KY-F55B) connected with a Leitz diaplan light microscope;
original images were taken at 10 and analyzed using Image-
Pro Plus 6 software (Media Cybernetics, Inc.).
Four-m-thick dewaxed sections were used for immunohis-
tochemical studies. Capillary density was assessed by a poly-
clonal antibody against vonWillebrand factor (vWF). Stem cell
recruitment (mesenchymal cells or mononuclear cells) into the
infarcted myocardium was assessed using antibodies directed
against Stro-1 and c-Kit antigens, respectively. Cycling cells
were identified with an antibody against nuclear transcription
factor Ki-67. The accumulation and the spatial distribution of
acetyl-histones was investigated with an antibody directed
against acetyl-histoneH4. Perivascular cells were characterized
using antibodies against NG2 and PDGF-R, and expression of
vascular endothelial growth factor (VEGF) was detected with
an antibody recognizing all VEGF isoforms. Specimens were
deparaffinated with xylene, rehydrated through decreasing
concentrations of ethanol, rinsed in distilled water, and sub-
jected to an antigen retrieval treatment. Antigens were
unmasked with citrate buffer, pH 6.0, at 120 °C, 1 atm for 21
min. After cooling and washing, endogenous peroxidase
activity was neutralized using a 3% H2O2 solution in metha-
nol absolute for 10 min at room temperature in the dark;
sections were then processed for immunohistochemistry
with a non-biotin-amplified method (NovoLinkTM Polymer
Detection System, Novocastra Laboratories Ltd.). After
washing with 1 TBS, the slides were incubated with Novo-
castraTM protein block for 5 min in a wet chamber to reduce
the nonspecific binding of primary antibody and polymer
reagent and rinsed twice with 1 TBS. Tissue sections were
subsequently stained using monoclonal antibodies against
Stro-1 (1:100; R & D Systems, Inc.), Ki-67 (1:230, clone
MM1; Novocastra), NG2 (1:100; R&D Systems, Inc.),
PDGF-R (1:100; R&D Systems, Inc.), and polyclonal anti-
bodies against acetyl-histone H4 (1:150, Lys8; Upstate Bio-
technology), c-Kit (1:200, DakoCytomation), VEGF (1:50,
JH121 clone; Abcam), vWF (1:2000; DakoCytomation) in 1%
bovine serum albumin in PBS overnight at 4 °C. After wash-
ing, slides were incubated for 30 min at room temperature
with NovocastraTM post-primary block to enhance penetra-
tion of the next polymer reagent, rinsed in 1 TBS, and
incubated with NovoLinkTM Polymer for 30 min at room
temperature. After washing, the sections were exposed to
the substrate/chromogen 3,3-diaminobenzidine prepared
from NovocastraTM 3,3-diaminobenzidine chromogen and
FIGURE 1. MRI-derived measures of left ventricular function. Global (A)
and regional (B) LV function are shown. Values are means  S.E.; n  11
animals for each experimental condition. LVEF, LV ejection fraction; CO, car-
diac output; LVEDV, LV end diastolic volume; LVESV, LV end systolic volume;
ED, end diastolic; ES, end systolic. The HBR-treated group received 100 l of
HBR solution (0.2 mg of HBR/100 g of rat weight). *, p 0.05 versus SHAM; †,
p  0.05 versus MI  PBS (one-way analysis of variance with subsequent
Bonferroni test).
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NovoLinkTM 3,3-diaminobenzidine substrate buffer, rinsed
in distilled water, and counterstained with Gill’s hematoxy-
lin. Then samples were dehydrated, coverslipped, and
viewed by light microscopy using the Image-Pro Plus pro-
gram. Negative control was obtained by omitting the pri-
mary Abs. Assessment of apoptotic programmed cell death
by terminal deoxynucleotidyltransferase-mediated dUTP
nick end labeling assay is described in the supplemen-
tal material.
Immunofluorescence—To investigate the co-expression of
different antigens in the same cell, a double immunofluores-
cence procedure was used. We aimed to demonstrate whether
Stro-1-positive cells co-expressed c-Kit, vWF, CD45, and
-sarcomeric actin, respectively. Four-m-thick dewaxed sec-
tions were rehydrated with decreasing concentrations of etha-
nol and rinsed in distilled water. Antigen retrieval was per-
formed as described above. Then
sections were incubated for 30 min
at room temperature in a wet cham-
ber with blocking solution contain-
ing sheep serum (1:10) in 1% bovine
serum albumin to reduce nonspe-
cific staining. Tissue sections were
labeled with the Stro-1 monoclonal
antibody (1:100; R&D Systems) at
37 °C for 45 min in a wet chamber.
After rinses, slides were incubated
with a Cy3-conjugated sheep anti-
mouse secondary antibody (1:1000;
Sigma), in 1%bovine serumalbumin
in PBS for 45 min at 37 °C; sections
were then treated with goat serum
(1:10) or 2% rabbit serum in 1%
bovine serum albumin in PBS for 30
min at room temperature and
stained with anti-CD45 (1:100;
Santa Cruz Biotechnology, Inc.) or
anti -sarcomeric actinmonoclonal
antibody (1:500; Sigma) or anti-c-
Kit (1:200; DakoCytomation) or
anti-vWF polyclonal antibodies
(1:2000; DakoCytomation); all im-
munostainings were performed for
45 min at 37 °C in the dark. The
slides were then incubated in
polyclonal goat anti-rabbit fluo-
rescein isothiocyanate-conjugated
(fluorescein isothiocyanate, 1:500;
Sigma) or rabbit anti-mouse fluo-
rescein isothiocyanate-conjugated
(fluorescein isothiocyanate, 1:250;
DakoCytomation) antibodies for
45 min at 37 °C in the dark. Finally,
after several rinses, the samples
were coverslipped with ProLong
antifade reagent with 4,6-dia-
midino-2-phenylindole (Molecu-
lar Probes). For negative control,
sections were processed omitting the primary antibody.
Gene Expression—Total RNA was extracted using TRIzol
reagent (Invitrogen), and 1 g was reverse-transcribed into
cDNA in a 21-l reaction volume with SuperScriptTM III
reverse transcriptase. To assess gene expression, 2 l of cDNA
were used for Real Time PCR performed with a Lightcycler
system (Roche Applied Science) and with the SYBR Green I
FastStart kit (Lightcycler FastStart DNA MasterPLUS SYBR
Green I) following the manufacturer’s instructions. Primer
sequence is reported in the supplemental material.
Data were normalized using GAPDH as an index of cDNA
content after reverse transcription. Amplification included ini-
tial denaturation at 95 °C for 10 min, 50 cycles of denaturation
at 95 °C for 10 s, annealing at 59–63 °C for 6–10 s, and exten-
sion at 72 °C for 10 s, performed at a temperature transition rate
of 20 °C/s. Fluorescencewasmeasured at the end of each exten-
FIGURE2.MRIdelayedcontrast enhancementofmyocardial scar. Top, representative LV short and longaxis
gadolinium-delayed contrast-enhanced MRI images for each experimental condition. Bottom, regional LV
delayed enhancement in infarcted LV treated with 100 l of HBR solution (0.2 mg of HBR/100 g of rat weight)
or PBS. Values aremeansS.E.;n11animals for eachexperimental condition. SA, short axis; LVDE, LVdelayed
contrast enhancement. *, p 0.05 versus SHAM; †, p 0.05 versusMI PBS (one-way analysis of variancewith
subsequent Bonferroni test).
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sion step. Specificity of the product was determined by a
melting curve analysis, conducted after completion of the
cycling process with the aid of a temperature ramp (from 55
to 95 °C at 0.1 °C/s) and continuous fluorescence monitor-
ing. Samples were run in duplicate, and the average thresh-
old cycle (Ct) value was used for calculations. Relative quan-
tification of mRNA expression was calculated with the
comparative Ct method using the “delta-delta method” for
comparing relative expression results between treatments in
real time PCR (11).
Nuclear Run-off TranscriptionAssay—Isolation of nuclei and
assessment of nuclear purity were performed as detailed else-
where (3). Only freshly isolated nuclei were used in each ex-
periment. Nuclear run-off experiments were carried out as
described previously (3). Nuclear RNA was isolated by using
guanidine thiocyanate and acid phenol extraction, followed by
purification on RNAMATRIXTM. Equal counts of 32P-labeled
RNA (about 5 106 cpm)were then
subjected to a solution hybridiza-
tion RNase protection assay and
were hybridized for 12 h at 55 °C in
the presence of unlabeled antisense
VEGF and pim-1mRNA. To gener-
ate these cRNA probes, cDNA frag-
ments of rat VEGF (597 bp), pim-1
(609 bp), or GAPDH (574 bp) genes
were inserted into a pCRII-TOPO
vector. Transcription of plasmids
linearized with BamHI generated
antisense strands of Pim-1 and
GAPDHmRNA, whereas transcrip-
tion of plasmids linearized with
XbaI produced an antisense strand
of VEGFmRNA. Samples were then
incubated with a combination of
RNase A and T1 and exposed to
proteinase K. The protected frag-
ments were recovered after phenol
chloroform extraction and electro-
phoretically separated in a poly-
acrylamide non-denaturing gel. Auto-
radiographic exposure was for 48 h.
In Vitro Vasculogenesis Assay—
Analysis of capillary-like tube for-
mation was performed using extra-
cellular matrix gel (Sigma). Fifty l
of gel matrix solution, diluted 1:2
with Dulbecco’s modified Eagle’s
medium, was applied to each well
on a 96-well plate and incubated for
1 h at 37 °C. Human umbilical vein
endothelial cells (HUVECs) (Lonza)
and rat aortic endothelial cells
(RAOECs) (Cell Applications, Inc.)
were cultured in endothelial growth
medium (EGM-2 from Lonza and
RAOEC growth medium from Cell
Applications, Inc., respectively)
until confluence. They were then trypsinized and seeded on the
preprepared polymerized gel. For each well, 1 104 cells were
suspended in 50 l of conditioned medium obtained from rat
neonatal cardiomyocytes (RCm) (Cell Applications, Inc.) or rat
Stro-1-positive cells (ScienCell) cultured for 24 h in the absence
or presence of HBR (2 mg/ml) and incubated at 37 °C. Capil-
lary-like structures were observed after 2 h and at regular inter-
vals during the following 24 h and photographed using an
inverted optical microscope equipped with a digital sight cam-
era (Nikon).
Enzyme-linked Immunosorbent Assay—VEGF and hepato-
cyte growth factor (HGF) were determined in supernatants
harvested fromRCm and Stro-1-positive cells cultured in the
presence or absence of HBR (2 mg/ml) at different times (12
h, 24 h, 3 days, and 6 days) by using commercially available
kits (rat VEGF enzyme-linked immunosorbent assay kit
(R&D Systems) and rat HGF enzyme-linked immunosorbent
FIGURE 3.Myocardial glucose uptake measured by [18F]FDG. Top, representative LV polar map, short and
long axis mPET images for each experimental condition; Bottom, mean score values of myocardial [18F]FDG of
infarcted LV treated with 100l of HBR solution (0.2 mg of HBR/100 g of rat weight) or PBS. n 11 animals for
each experimental condition. SA, short axis; LA, long axis. a.u., arbitrary units.
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assay kit (B-Bridge International)), according to the user
manual. All samples were assayed at least in duplicate.
Western Blotting—Total heart lysate and total lysate of RCm
and Stro-1-positive cells were subjected to SDS-PAGE. Acetyl-
histone H4 and GAPDH were detected by incubation with a
polyclonal rabbit Lys8-acetyl-histone H4-specific antibody
(1:1000 dilution; Upstate Biotechnology) and a monoclonal
rabbit GAPDH-specific antibody (1:1000 dilution; Cell Signal-
ing), respectively, followed by incubation with horseradish per-
oxidase-conjugated antibody to rabbit IgG (Cell Signaling).
Antigen-antibody complexes were visualized by using ECL
Western blotting detection reagents
(GE Healthcare) according to the
manufacturer’s instructions.
Statistical Analysis—Statistical
analysis was performed using
GraphPad Prism, version 4. Data
were evaluated by using a two-
tailed, unpaired Student’s t test and
analysis of variance as appropriate,
with the Bonferroni post hoc test,
assuming a p value less than 0.05 as
the limit of significance.
RESULTS
The glycoconjugate HBR is an
ester between the hydroxyl groups
of hyaluronan (HA) and the car-
boxyl groups of both butyric acid
(BU) and retinoic acid (RA). All of
the synthesized HBR exhibited a DS
with BU (DSBU) ranging between
0.05 and 1.5, whereas the DS with
RA (DSRA) was between 0.002 and
0.1. The DSBU/DSRA ratio was at
least 6. In the HBR used in the pres-
ent study, DSBU andDSRAwere 1.44
and 0.032, respectively. The weight-
average molecular weight ranged
between 10,000 and 30,000 daltons.
HBR Induced No Adverse Effects
in Healthy Rats—No adverse reac-
tions were observed during and
after intramyocardial injection of
HBR in healthy rats. Within 4
weeks, the animals exhibited no
cardiovascular complications, such
as arrhythmias, pulmonary edema,
ascites, or thrombosis. Animal
behavior was normal. Histological
analysis did not show interstitial
edema and inflammatory infiltrates.
HBR Injection into the Infarcted
Myocardium Enhanced Myocardial
Performance—MRI analysis showed
a marked recovery of cardiac per-
formance in infarcted rats treated
with HBR, compared with un-
treated animals (supplemental Movies 1 and 2). The ejection
fraction and cardiac output remarkably recovered in infarcted
rats receiving HBR, with significant reduction in LV end dia-
stolic volume 4 weeks after MI (Fig. 1A). No major recovery of
LV global function was observed 1 or 2 weeks following the
injection of HBR (data not shown). LV end systolic wall thick-
ening, an index of regional contractile function, and LV end
diastolic thickness, an index of regionalmass, were preserved in
the LV border zone of infarcted HBR-treated hearts (Fig. 1B).
Conversely, no increase in contractility and mass was observed
in the remote zone (Fig. 1B). Cardiac MRI was performed to
FIGURE 4. HBR increased the number of capillary vessels, Stro-1-positive cells, and perivascular ele-
ments. A–C, 4 weeks followingmyocardial infarction. Transversally cut left ventricular myocardium fromHBR-
treated (100 l of HBR solution) hearts showed a reduced scar, compared with PBS-treated animals (A, upper
images, arrows demarcate the infarcted area). Picro-Mallory stains in blue the area of scar and in red the myo-
cardium parenchyma. In the border zone of HBR-treated hearts, scar reduction was associated with fewer
apoptotic cardiomyocytes (A, lower images; scale bars, 20 m) and increased number of capillary vessels (B).
vWF expression highlights endothelial cells (arrows) lining the capillary inner wall (B, scale bars, 300m (upper
images) and 50m(lower images).C, inHBR-treated samples, Stro-1 positive cells (arrows) increased in number
andwere closely associatedwith the outer capillary wall, whereas c-Kit-positive cells did not vary significantly,
comparedwith untreated animals. Scale bars, 20m.D–F, 24 h followingmyocardial infarction.D, the number
of Ki-67-positive cells significantly increased in the HBR-treated animals (arrows); scale bars, 50 m. E, cells
expressing NG2 and PDGF-R (arrows); scale bars, 30 m (upper images) and 100 m (lower images). F, VEGF
expression (arrows). Scale bars, 100m (left andmiddle images) and 50m (right image). *, significantly differ-
ent from PBS-treated hearts, p 0.05 (statistical test: two-tailed, unpaired Student’s t test). IHC, immunohisto-
chemistry. Full-size images of each individual panel are presented in supplemental Fig. 1.
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FIGURE 5. HBR affects gene expression and secretion of trophic mediators. A and B, VEGF, kdr, HGF, akt, and pim-1 gene expression was assessed by
real-time PCR. RCm (A) or Stro-1 cells (B) were cultured for 24 h (black bar), 3 days (dark gray bar), and 6 days (light gray bar) in the absence or presence of HBR
(2mg/ml). The abundance of eachmRNA in untreated cells was defined as 1, and the amounts of VEGF, kdr, HGF, akt, and pim-1mRNA fromHBR-treated cells
were plotted relative to that value (mean S.E.; n 6).C–F, time course analysis of VEGF andHGF, respectively, released by RCm (C and E) or Stro-1 cells (D and
F) cultured in the absence (black bar) or presence (gray bar) of HBR (mean  S.E.; n  6). *, significantly different from untreated cells (controls), p  0.05
(GraphPad Prism version 4 (available on theWorldWideWeb), two-tailed, unpaired Student’s t test).G, in vitro capillarogenesis was assessed in HUVECs (a and
c) and RAOECs (b and d) exposed to a conditionedmediumobtained fromRCmor Stro-1 cells cultured for 24 h in the absence (black bar) or presence (gray bar)
of HBR. Morphological characteristics of capillary-like networks were evaluated by using NIS-Elements D Nikon software (version 3.06). Data are the mean
S.E.; n 3. *, significantly different fromHBR; #, significantly different fromHBR; p 0.05.
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detect scar tissue, which appears hyperintense, and for infarct
size assessment in LV injected with PBS or HBR (Fig. 2, top). It
is noteworthy that we found a significant reduction in the
extension of the delayed enhancement of the LV infarct zone in
HBR-injected hearts compared with the untreated group (Fig.
2, top and bottom).
HBR Primed Recovery of Cardiac [18F]FDG Uptake—Fig. 3
displays a polar map of regional distribution and short and long
axis images of [18F]FDGuptake in each experimental condition.
The ischemic injury in the anterior wall significantly recovered
in infarcted hearts receiving HBR (Fig. 3). Glucose metabolism
assessed by [18F]FDG uptake, an index of myocardial viability,
was also preserved in the border and remote regions of
infarcted, HBR-treated hearts (Fig. 3).
HBR IncreasedCapillaryDensity and Induced Recruitment of
Stro-1-positive Cells—Gross pathologic examination of ische-
mic myocardium after nitro blue tetrazolium staining revealed
that HBR injection substantially decreased the percentage of
LV occupied by fibrosis. Picro-Mallory trichrome staining and
quantitative analyses showed that the infarct area was signifi-
cantly smaller in animals receiving HBR than in the untreated
group (Fig. 4A, upper images). Interestingly, in many of the
HBR-treated samples, the blue-stained areas, reflecting infarct
scarring, were mainly confined to a limited area in the sub-
endocardial zone, which also exhibited regions of viable, red-
stained tissue. A terminal deoxynucleotidyltransferase-me-
diated dUTP nick end labeling assay kit demonstrated that
HBR-treated hearts exhibited a decreased number of apo-
ptotic cardiomyocytes when compared with untreated
hearts (Fig. 4A, lower images).
Immunohistochemical analysis
of vWF expression revealed that the
density of capillary vessels was sig-
nificantly increased at the infarct
border zone of animals injected
with HBR, as compared with in-
farcted tissue receiving saline as a
placebo (Fig. 4B). Unlike control
samples, in the HBR-treated tissue
sections, the regeneration of vWF-
positive vascular structures was
associated with the presence of
loose connective tissue in which
scattered round and spindle ele-
ments were seen embedded; in
some samples, this “vascular front”
extended from the subepicardial
ventricular myocardium and spread
into adjacent clusters of “viable” car-
diomyocytes. Immunohistochemis-
try revealed an increased number of
perivascular Stro-1-positive cells
near newly formed capillaries in
HBR-treated hearts after 4 weeks,
significantly exceeding the few Stro-
1-positive cells detected in the non-
injected group (Fig. 4C). Interest-
ingly, most of the Stro-1-positive
cells lacked staining with vWF (data not shown). On the con-
trary, some Stro-1-positive cells coexpressed cardiac -sarco-
meric actin (data not shown). On the whole, differently from
the Stro-1 expressing elements, the number of c-Kit-positive
cells did not differ significantly among treated and untreated
animals. This discrepancy may suggest that, at 4 weeks, Stro-1-
resident perivascular mesenchymal cells but not c-Kit bone
marrow-derived mononuclear cells were selectively embedded
in the site of tissue repair following HBR injection.
The presence of Ki-67 was used to determine whether there
were cycling cells in themyocardium at the time of sacrifice; after
24 h, a significant increase in Ki-67 expression was found in the
examined sections fromHBR-injected animals, as compared with
theuntreatedgroup (Fig. 4D). In theHBR-treatedhearts, theKi-67
nuclear antigen was markedly expressed by perivascular spindle-
and round-shaped stromal cells located between cardiomyocytes.
These cells expressedNG2 and PDGF-R (Fig. 4E), a set of mark-
ers thathavebeenpreviously showntorepresentaphenotype indi-
cator of pericyte/perivascular identity (12). The same cells lacked
expression of hematopoietic cell markers (data not shown). Other
Ki-67-positive cytotypes included endothelial cells and polymor-
phonuclear leukocytes. VEGF cytoplasmic expression also signifi-
cantly increased in the cardiomyocytes following HBR injection
(Fig. 4F).
HBR Enhanced the Gene Expression and Secretion of Angio-
genic, Antiapoptotic, and Antifibrotic Factors in Both Rat Ven-
tricular Cardiomyocytes and Stro-1-positive Stem Cells—The
infarctedmyocardium has been shown to release a number of
factors, including the granulocyte colony-stimulating factor
and the granulocyte-macrophage colony-stimulating factor,
FIGURE 6. Comparative analysis of the effect of HBR, HA, BU, and RA on the secretion of VEGF from
rat Stro-1 positive cells. Cells were incubated for the indicated times in the absence or presence of 2.0
mg/ml HBR, 1.5mg/ml HA, 2.5mM BU, or 108 M RA alone or exposed to a hydrolyzed (HY) HBR solution (2.0
mg/ml), obtained from a 2-h basic HBR hydrolysis followed by pH neutralization. This procedure has been
shown to afford a complete release of each single HBR grafted moiety (C. Ventura et al., unpublished
observations). Data are the mean  S.E. of four separate experiments. *, significantly different from HBR
alone (GraphPad Prism version 4 (available on theWorldWideWeb), two-tailed, unpaired Student’s t test).
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involved in bone marrow cell mobilization and homing (13,
14). No significant difference in plasma levels of each factor
was observed throughout a 24-h period between rats sub-
jected to MI in the absence or presence of HBR (data not
shown).
Real-time PCR analysis revealed that in vitro exposure to
HBR of both RCm and rat Stro-1-positive stem cells signifi-
cantly enhanced the gene expression of VEGF, kdr (encoding a
major VEGF receptor), HGF, akt, and pim-1 (Fig. 5,A andB). In
RCm, HBR-mediated stimulation of pim-1 gene expression
occurred in a time-dependent, biphasic fashion. Increased
pim-1 mRNA was detected within 24 h after HBR stimulation
and then declined toward basal values after 3 days. A second
elevation in pim-1 gene expression was observed after 6 days of
RCm exposure to the mixed ester (Fig. 5A).
The HBR treatment enhanced the secretion of VEGF and
HGF in the culture medium from both RCm and Stro-1 cells.
Time course analyses revealed that the stimulatory action pro-
gressively increased during the first 24 h, persisting throughout
a 6-day period (Fig. 5, C–F). HBR did not appreciably affect the
secretion of VEGF or HGF fromHUVECs or RAOECs; nor did
it induce these cells to form capillary-like structures in a semi-
solidmedium in vitro (data not shown). However, a remarkable
increase in capillarogenesis was observedwhen eitherHUVECs
or RAOECs were cultured with medium obtained from car-
diomyocytes or Stro-1-positive cells exposed to themixed ester
(Fig. 5G). The amount of VEGF released by Stro-1 cells was
slightly increased by BU but not HA alone, being significantly
augmented by 108 M all-trans-RA, and further enhanced fol-
lowing exposure to hydrolized HBR, resulting in the release of
all moieties grafted within the
mixed ester (Fig. 6). Nevertheless,
under these experimental condi-
tions, the yield of growth factor
secretion was considerably lower
than that detected in HBR-ex-
posed cells (Fig. 6). Cumulatively,
these findings suggest the activa-
tion of prominent paracrine
effects by HBR on both cell popu-
lations, enhancing the expression
of cytokines and genes with a cru-
cial role in cell survival and
angiogenesis.
HBR Acted at the Transcriptional
Level—To further dissect the cellu-
lar response toHBR, nuclear run-off
experiments were designed to
assess whether HBR may have
affected the rate of gene transcrip-
tion and whether, in the affirmative,
it may have acted as a unit or after
hydrolysis of hyaluronan grafted
moieties. Fig. 7 shows that nuclei
isolated from HBR-treated Stro-1-
positive cells exhibited a consistent
increase in the transcription rate of
VEGF and pim-1 genes, as com-
pared with nuclei isolated from
untreated cells. In separate experi-
ments, nuclei were isolated from
FIGURE 7. Analysis of VEGF and pim-1 gene transcription in isolated
nuclei. A and B, nuclei were isolated from rat Stro-1-positive cells cultured for
24 h (VEGF gene transcription) or 6 days (pim-1 gene transcription) in the
absence or presence of 2.0 mg/ml HBR, respectively. From lanes C–H, nuclei
were isolated from untreated cells and then directly incubated for 12 h with-
out any drug (C) or in the presence of 2.0mg/ml HBR (D), 1.5mg/ml HA (E), 2.5
mM BU (F), 108 M RA (G), or with a combination of BU and RA (H). Autoradio-
graphic exposure was for 2 days on Kodak X-Omat film with an intensifying
screen. The right side of each panel shows the position of radiolabeled DNA
markers, showing that the singleprotected fragmentsmigratedwithamolec-
ular size comparable with that of VEGF (597 bases), pim-1 (609 bases), or
GAPDH (574 bases) mRNA. Due to the similar size of VEGF-, pim-1-, and
GAPDH-protected fragments, 32P-labeled nuclear RNA was hybridized sepa-
rately with cRNA probes, and the corresponding hybrids were run onto dif-
ferent gels. Autoradiograms are representative of six separate experiments.
FIGURE 8. Time course analysis of the effect of HBR on myocardial histone acetylation. Western blot
analysis of histoneH4 acetylationwas performed in total tissue extracts fromborder (BZ) and remote zone (RZ)
of infarcted hearts (MI) 6 or 16 h (A) or 24 h (B) after injection in the absence (PBS) or presence of 100l of HBR
solution (0.2mgofHBR/100gof ratweight). GAPDHwasusedas a loading control. Acetylation levelwas estimated
bydensitometricquantification(n3). *, significantlydifferent fromthesamecontrol timepointwithintheMIBZ(A)
or from MI BZ or MI RZ (B). p  0.05 (GraphPad Prism version 4 (available on the World Wide Web), two-tailed,
unpaired Student’s t test). All Western blots were performed at least three timeswith similar results.
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untreated cells and subsequently incubated with HBR or
exposed to HA, BU, or RA administered alone or in combina-
tion. Although nuclear exposure to HBR or HA failed to trigger
a transcriptional response, the incubation with BU or RA
enhanced gene transcription (Fig. 7). The transcription ratewas
further enhanced when nuclei were exposed to a combination
of BU and RA (Fig. 7).
HBR Increased Histone Acetylation—Western blot analysis
performed in tissue extracts revealed that, consonant with pre-
vious observations (15, 16), histoneH4 acetylation decreased in
the infarcted hearts. Six h after HBR injection, acetyl-histone
H4 signal rose in the border zone, progressively increasing up to
16 h, as compared with the untreated group (Fig. 8A). After
24 h, histone H4 acetylation increased both in the border and
remote zone of infarcted HBR-injected hearts, as compared
with the non-injected tissue (Fig. 8B). Following HBR treat-
ment, a more pronounced signal was detected in the border
zone, compared with the remote area. Akin to Western blot
studies, immunohistochemical analyses showed an overall
increase in the signal of acetyl-histone H4 in hearts of HBR-
treated animals, as compared with untreated hearts (Fig. 9A).
The number of cardiomyocyte nuclei stained with acetyl-his-
toneH4 antibodywas significantly increased byHBR treatment
in the border zone (Fig. 9A). In vitro experiments provided evi-
dence that acetyl-H4 immunoreactivity was also higher in
HBR-exposed RCmand Stro-1-positive cells, as comparedwith
unexposed cells (Fig. 9B).
DISCUSSION
The present study shows for the first time that acutemyocar-
dial injection of HBR, a hyaluronan ester previously shown to
enhance hMSC-mediated cardiac repair in vivo (3), rescued
infarcted rat hearts by increasing vascularization, promoting
cardiomyocyte survival, and restoring normal tissue function.
The HBR action involved an early increase in the number of
pericytes, a reserve of progenitor cells that may be integral to
the origin of MSCs and other related adult stem cells (12), sug-
gesting a role of perivascular cells in capillary density enhance-
ment and tissue repair elicited by the mixed ester.
It is now evident that an extremely limited percentage of
stem cells will engraft and survive within the recipient myocar-
dium following intracoronary infusion or transendocardial
injection (17). Moreover, the use of injectable scaffolds to aug-
ment stem cell engraftment is not devoid of harmful decrease in
myocardial perfusion. Hence, the development of deliverable
molecules promoting paracrine mechanisms of cardiac repair
and survival of endogenously recruited stem cells, without
immediate need of stem cell transplantation, would have
remarkable biomedical implications. Here, we show that HBR
may fulfill both requirements. Four weeks after HBR injection,
a significant increase in perivascular Stro-1-positive cells could
be detected within the infarcted hearts. This effect was associ-
ated with a reverse myocardial remodeling (decrease of fibrosis
and dilatation) and consistent increase in myocardial perform-
ance. A possible explanation may result from in vivo studies
demonstrating that HBR-treated hearts had a significant
decrease of apoptotic cardiomyocytes, as revealed by a terminal
deoxynucleotidyltransferase-mediated dUTP nick end labeling
assay, as well as from in vitro experiments showing enhanced
gene expression and secretion of VEGF and HGF in both RCm
and Stro-1-positive cells exposed to HBR. Growth factor secre-
tion may have primed a proangiogenic context (18), reinforced
by the stimulatory effect of HBR on the expression of the kdr
gene, encoding a VEGF receptor involved in autocrine/para-
crine amplification of VEGF secretion and angiogenic signaling
(19, 20). Moreover, HGF gene transfer into the myocardium
improved myocardial function and geometry (21), due to anti-
fibrotic effects through inhibition of transforming growth fac-
tor- expression. HBR-mediated recruitment of both myocar-
dial and Stro-1 cells into a proangiogenic paracrine circuitry of
cardiac repair is further supported by the finding that (i) an
increase in capillarogenesis was induced in vitro in both
HUVECs and RAOECs with a medium obtained from HBR-ex-
posed cells; (ii) no secretion of VEGForHGFor in vitro angiogen-
esis was found following a direct HUVEC or RAOEC exposure to
HBR; and (iii) in vivo, a large number of capillary vessels in HBR-
injected hearts were “decorated” by Stro-1-positive cells, lacking
the expression of vWF, an endothelial marker. Although some
Stro-1-positive cells in HBR-injected hearts expressed heart-spe-
cific -sarcomeric actin, these few elements appeared to lack
mature sarcomeric organization, and their role in rescuing
infarctedmyocardium remains questionable.
The observation that exposure of RCm and Stro-1 cells to
HBR increased VEGF, HGF, akt, and pim-1 gene expression
may have further relevant implications. These genes are deeply
involved in cardioprotective signaling, including antiapoptotic
and antifibrotic responses (21–25). Enhanced expression of
both akt and pim-1 promotes cardiomyocyte survival and
growth in transgenicmice subjected to acutemyocardial infarc-
tion (26, 27). Here, we show that in RCm pim-1 gene expression
was augmented in a biphasic manner by the addition of HBR.
Biphasic kinetics in pim-1 gene expression have been previ-
ously demonstrated in other cell types exposed to agents regu-
lating cell growth and differentiation (28, 29) and appeared to
involve a complex interplay between cell signaling networks,
cell cycle progression, gene transcription, and/ormRNA stabil-
ity (29). Cardiac control of Pim-1 gene expression is still poorly
understood, and future work is required to dissect the molecu-
lar mechanisms underlying Pim-1 regulation by HBR in myo-
cardial cells.
HBR may also have increased the survival and rescuing
potential of Stro-1-positive cells recruited to the injured myo-
cardium. In this regard, both VEGF and HGF have been shown
FIGURE 9. HBR increased histone acetylation in infarcted myocardium, isolated cardiomyocytes and Stro-1 cells. A, immunohistochemistry of acetyl-
histone H4. Acetylation level was estimated in infarcted hearts by intensity quantification and counting of stained cardiomyocyte nuclei 24 h after injection in
the absence (PBS) or presence of HBR solution (0.2 mg of HBR/100 g of rat weight). Scale bar, 30 m. *, significantly different from PBS-treated, p  0.05.
B, Western blot analysis of total cell extracts from RCm and Stro-1-positive cells cultured in the absence (CTR) or presence of HBR (2 mg/ml) (n  3). *,
significantly different from the same control time point, p 0.05 (GraphPad Prism version 4 (available on theWorldWideWeb), two-tailed, unpaired Student’s
t test). All Western blots were performed at least three times with similar results.
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to promote MSC survival and therapeutic potential (30),
enhancing stem cell-mediated cardioprotection in infarcted
hearts (31, 32). Up-regulation of both akt and pim-1 gene
expression inHBR-treated Stro-1 cells is also worthy of consid-
eration, due to the prominent role of these serine/threonine
kinases in stem cell survival and differentiation (30, 33). MSCs
overexpressing akt prevent remodeling and restore perform-
ance of infarcted hearts (1, 34). Moreover, pim-1 has been
shown to be required for endothelial and mural cell differenti-
ation in vitro (35).
It is relevant that a “program” of genes involved in cardiac
protection and stem cell survival can be chemically induced by
a syntheticmolecule, without the need of viral vector-mediated
gene transfer technologies. The molecular dissection of mech-
anisms underlyingHBR-mediated responses in vitro and in vivo
remains to be fully elucidated. The finding that VEGF secretion
from these cells was significantly higher in the presence ofHBR,
as compared with the response to HA, BU, or RA alone, or to a
mixture of the three moieties released by hydrolized HBR sug-
gests that a maximal response may be achieved when both BU
and RA are concomitantly internalized by the mixed ester.
Probably, the exposure to HBR may have afforded an optimal
intracellular BU/RA ratio and/or timely action. To this end,
nuclear run-off experiments indicate that the action of HBR
was mediated at the transcriptional level and that although the
transcription rate of VEGF and pim-1was unaffected following
nuclear exposure to HBR, it was conversely enhanced by BU
and RA with superimposable time courses and additive effects.
These results also prompt the hypothesis that, at least at the
nuclear level, HBR may have acted following the hydrolysis of
its grafted moieties.
HBR-induced transcriptionmay be related, at least in part, to
the observed increase in histone acetylation, probably attribut-
able to a decrease inHDAC activity by the butyricmoiety of the
mixed ester. It is evident that chromatin remodeling by HDAC
inhibitors can largely affect transcription factor accessibility to
target cis-acting regulatory sites (36). These so-called epige-
netic changes have profound effects on gene expression, both in
physiological and pathological processes (36). An inference of
the retinoid moiety of HBR with the observed changes in gene
expression is supported by the finding that retinoic acid plays a
crucial role in mammalian vascular development (37) and
enhances angiogenesis by triggering VEGF, kdr, and HGF gene
transcription and signaling (38). Moreover, retinoid X recep-
tor/retinoic acid receptor heterodimer action is enhanced by
histone deacetylase inhibitors, promoting major developmen-
tal pathways in pluripotent cells (39). Studies are in progress to
further address the spectrum of growth factor and transcrip-
tional profiles recruited by HBR.
The finding that a synthetic glycoconjugate displays a thera-
peutic effect in the acute phase ofMImay have several biomed-
ical implications. In fact, the clinical use of human adult stem
cells will be hampered in the near future by a number of inter-
related challenges, including (i) high throughput bioprocess
development and improved downstream processing problems;
(ii) significantmodification, improvement, and retesting of cur-
rent strategies of stem cell culturing and cardiovascular com-
mitment complying with all standards of good manufacturing
practice; and (iii) analytical methodologies for control of good
manufacturing practice bioprocessing and differentiation effi-
ciencies. Therefore, the timing for cell culture and expansion
within a goodmanufacturing practice settingwill involve a sub-
stantial delay (several weeks) in autologous stem cell transplan-
tation with respect to the acute phase of a heart attack. Mean-
while, the cardiac repair afforded by a myocardial injection of
HBR may serve as first aid to rescue a damaged heart. This
intervention may be followed by delayed transplantation of
autologous stem cells, eventually preconditioned ex vivo with
the same molecule, to enhance the long term potential for car-
diovascular cell therapy.
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